Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo.
One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease. This can be avoided by removing the mature T cells from the marrow, most conveniently by the use of monoclonal antibodies. However, T cell purging results in an increased tendency for the recipient to reject the donor marrow. We have developed monoclonal antibodies to L3/T4 and Lyt-2 that specifically deplete functional T cell subsets in mice. We demonstrate that such reagents can be used to control both graft-versus-host disease and marrow rejection in mouse models of bone marrow transplantation across one-haplotype or two-haplotype major histocompatibility differences. Such strategies to abrogate host resistance, by administration of anti-T-cell monoclonal antibodies to the recipient, may complement marrow T cell purging for human allogeneic bone marrow transplantation.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D016026:Bone Marrow Transplantation; D002678:Chimera; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000517:prevention & control*; D007121:Immunocompetence; D007518:Isoantibodies / Q000276:immunology; D008212:Lymphocyte Depletion / Q000379:methods*; D008285:Major Histocompatibility Complex; D051379:Mice; D008815:Mice, Inbred Strains / Q000276:immunology; D051381:Rats; D011919:Rats, Inbred Strains / Q000276:immunology; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D007518:Isoantibodies; C029805:Lyt antibodies